Holen Sie sich die Stockscreener-App
6.43
3.71%
0.23
Handel nachbörslich:
6.32
-0.11
-1.71%
Schlusskurs vom Vortag:
$6.20
Offen:
$6.15
24-Stunden-Volumen:
1.02M
Relative Volume:
0.94
Marktkapitalisierung:
$567.93M
Einnahmen:
$73.48M
Nettoeinkommen (Verlust:
$-108.30M
KGV:
-2.8578
EPS:
-2.25
Netto-Cashflow:
$-67.17M
1W Leistung:
+1.90%
1M Leistung:
+0.16%
6M Leistung:
+14.82%
1J Leistung:
+115.77%
1-Tages-Spanne:
$6.09
$6.48
1-Wochen-Bereich:
$6.09
$6.6691
52-Wochen-Spanne:
$2.61
$7.79
Personalis Inc Stock (PSNL) Company Profile
Firmenname
Personalis Inc
Sektor
Branche
Telefon
650-752-1300
Adresse
6600 DUMBARTON CIRCLE, FREMONT, CA
Vergleichen Sie PSNL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
6.43 | 557.33M | 73.48M | -108.30M | -67.17M | -2.25 |
|
TMO
Thermo Fisher Scientific Inc
|
427.62 | 157.79B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.91 | 138.02B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
532.00 | 42.36B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
116.19 | 32.08B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
187.38 | 27.28B | 15.50B | 1.33B | 2.16B | 7.34 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-15 | Eingeleitet | Guggenheim | Buy |
| 2025-03-17 | Eingeleitet | Craig Hallum | Buy |
| 2023-02-06 | Hochstufung | Needham | Hold → Buy |
| 2022-01-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-11-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-03 | Herabstufung | Needham | Buy → Hold |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-09-20 | Bestätigt | Needham | Buy |
| 2021-05-06 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2021-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-11-12 | Bestätigt | Needham | Buy |
| 2020-11-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-10-19 | Eingeleitet | Citigroup | Buy |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-08-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-08-18 | Eingeleitet | Needham | Buy |
| 2019-09-26 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-07-15 | Eingeleitet | BofA/Merrill | Neutral |
| 2019-07-15 | Eingeleitet | Cowen | Outperform |
| 2019-07-15 | Eingeleitet | Morgan Stanley | Overweight |
| 2019-07-15 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Personalis Inc Aktie (PSNL) Neueste Nachrichten
Personalis to Announce Second Quarter 2025 Financial Results - BioSpace
Is Personalis Inc. a good long term investmentOutstanding risk-reward balance - jammulinksnews.com
What analysts say about Personalis Inc. stockRapid growth opportunities - jammulinksnews.com
Personalis Inc. Stock Analysis and ForecastMassive stock growth - jammulinksnews.com
What drives Personalis Inc. stock priceOutstanding growth strategies - jammulinksnews.com
Personalis Strengthens Leadership: New VP Gets $631K Stock Option Package in Precision Oncology Push - Stock Titan
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | PSNL Stock News - GuruFocus
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Tempus AI, Inc. (TEM) and Personalis Join Forces to Take on Colorectal Cancer - Insider Monkey
From Clinics to Cancer Labs, AI Is Unlocking a New $100B+ Era in Medicine - Benzinga
How Personalis Inc. stock performs during market volatilityFree Access to Community with 300% Return - Newser
Why Personalis Inc. stock attracts strong analyst attentionFree Insider Trading Tips - Newser
What makes Personalis Inc. stock price move sharplyFree Investment Group - Newser
Personalis (NASDAQ:PSNL) Pulls Back 14% This Week, but Still Delivers Shareholders Splendid 284% Return Over 1 Year - 富途牛牛
Personalis, Inc. (PSNL) Stock Analysis: Navigating a 5.50% Revenue Growth Amidst Volatility - DirectorsTalk Interviews
Personalis (PSNL) Expands Partnership with Tempus AI for Cancer Detection - GuruFocus
Personalis and Tempus: Pioneering the Future of Colorectal Cancer Care Through Precision Diagnostics - AInvest
Personalis expands Tempus deal to include colorectal cancer testing - Seeking Alpha
Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients - businessnewsthisweek.com
Personalis and Tempus extend cancer detection collaboration to 2029 By Investing.com - Investing.com South Africa
Personalis and Tempus: A Cancer Detection Breakthrough with Multi-Billion-Dollar Implications - AInvest
Personalis extends Tempus agreement to add colorectal cancer indication By Investing.com - Investing.com South Africa
Personalis and Tempus extend cancer detection collaboration to 2029 - Investing.com Australia
Personalis Expands Tempus Strategic Collaboration to Bring Ultra - GuruFocus
Personalis extends Tempus agreement to add colorectal cancer indication - Investing.com
Personalis Expands Agreement with Tempus AI for Cancer Test - TipRanks
Personalis Expands Tempus AI Collaboration to Include Colorectal Cancer - HIT Consultant
Personalis Expands Tempus AI Collaboration to Include Colorectal Cancer Detection - MarketScreener
Finanzdaten der Personalis Inc-Aktie (PSNL)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.06%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):